Mexidol®-Anti-Age (anti-aging) drug

Time codes:
  • 00:00

    History of searching for ways to extend life

  • 00:19

    Inflaim theory and connection with the aging process

  • 00:35

    The role of oxidative stress in the development of inflammation

  • 00:45

    Pharmacological and non -pharmacological methods of exposure 

  • 01:01

    Mexidol® as a drug with multimodal effects

  • 01:45

    The ability of the drug Mexidol® to extend life and improve cognitive functions

Anton Pavlovich Pereverzev – PhD, Associate Professor of the Department of Therapy and Polymorbid Pathology of the Federal State Budgetary Educational Institution of Higher Professional Education, Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation

Announcement:

How does aging occur? What processes occur during this process? For a long time, science had no answers to these questions. However, with the advent of inflammaging theory, we have come closer to explaining this phenomenon. According to this theory, the aging process and the development of geriatric syndromes are associated with the progression of chronic, aseptic inflammation. This process is exacerbated by oxidative stress, which is one of the main causes of inflammation. This is where pharmacological and non-pharmacological methods come to the rescue. Mexidol®has been studied in laboratory animal studies, which demonstrated its ability to prolong life. Mexidol® hasantioxidant, antihypoxic, and membrane-stabilizing effects.

Block of articles on this topic

The connection of cellular aging, cardiovascular diseases and anxiety disorders

Author:
A.P. Pereverzev

FSBOU DPO RANMO of the Ministry of Health of Russia

The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)

Authors:
V.V. ZAKHAROV1, O.N. TKACHEV2,3, E.A. MKHITARYAN2,3, A.I. FEDIN2

Approaches to pharmacotherapy of vascular moderate cognitive disorders in patients of various age groups

Authors:
V.V. ZAKHAROV1, A.I. FEDIN2, E.A. MKHITARYAN2,3

Features of pharmacotherapy of vascular cognitive impairment in elderly people

Author:
A.N. BOGOLEPOVA1,2

1N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia;
2Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia, Moscow, Russia

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com